The transaction is sourced from an SEC EDGAR Form S-4 filing published on July 27, 2023. Based on the facts provided, the deal's status is pending regulatory approval.
On the financial advisory side, Cowen and Company, LLC served as financial advisor to Frequency Therapeutics and is identified as the lead advisor in this transaction. The source material is drawn from a consent letter dated July 13, 2023, addressed to the Board of Directors of Frequency, referencing Cowen's opinion letter included as an annex to the proxy statement/prospectus and cited under the headings "Prospectus Summary, Opinion of Frequency's Financial Advisor" and "The Merger, Opinion of Frequency's Financial Advisor." No financial advisor to Korro Bio is identified in the facts provided.
No legal advisor is identified for either party in the facts provided for this transaction.
Beyond confirming that the transaction is structured as a stock-for-stock reverse merger, no further detail on the specific exchange ratio or other terms of the stock consideration is included in the facts available.
Several elements of this deal remain undisclosed. The deal value is explicitly noted as not stated in the source document, and no legal advisor to either Korro Bio or Frequency Therapeutics is identified. No financial advisor to Korro Bio is named, and no expected closing date or detail on the specific exchange ratio is provided in the available material.